title: Oxidative metabolism of lansoprazole by human liver cytochromes P450.
abstract: The aim of this work was to identify the form(s) of human cytochrome P450 (P450) involved in the hepatic biotransformation of lansoprazole to its two main metabolites, i.e., the sulfone and the hydroxy derivative. In liver microsomes, the production of the sulfone of lansoprazole correlated with the level of P450 3A4, cyclosporin oxidase, and the production of the hydroxy derivative, as well as of omeprazole sulfone. The production of hydroxylansoprazole moderately correlated with the level of P450 3A4, cyclosporin oxidase, and (S)-mephenytoin 4'-hydroxylase. The production of the sulfone and of the hydroxy derivative of lansoprazole was significantly inhibited by anti-P450 3A4 antibodies, by cyclosporin and ketoconazole, and by tolbutamide. Anti-P450 2C8 and 2C3 antibodies moderately inhibited the biotransformation of lansoprazole, whereas they completely inhibited (S)-mephenytoin 4'-hydroxylase activity under the same conditions. In primary cultures of human hepatocytes, the biotransformation of lansoprazole and the oxidation of cyclosporin were strongly increased by rifampicin and phenobarbital, whereas (S)-mephenytoin 4'-hydroxylation was not. beta-Naphthoflavone did not induce the formation of the sulfones but stimulated the production of hydroxylansoprazole. Among several forms of cDNA-expressed human P450s, 3A4 generated significant amounts of the sulfones of lansoprazole and omeprazole and 2C18 was active for the production of hydroxylansoprazole but inactive in the 4'-hydroxylation of (S)-mephenytoin. We conclude that P450 3A4 is the major enzyme involved in the production of the sulfone of lansoprazole and that this P450, as well as P450 2C18 and/or another 2C-related form, could contribute to the production of hydroxylansoprazole.
authors.affiliation: INSERM U-128, CNRS, Montpellier, France.
authors.forename: L
authors.initials: L
authors.lastname: Pichard
authors.forename: R
authors.initials: R
authors.lastname: Curi-Pedrosa
authors.forename: C
authors.initials: C
authors.lastname: Bonfils
authors.forename: E
authors.initials: E
authors.lastname: Jacqz-Aigrain
authors.forename: J
authors.initials: J
authors.lastname: Domergue
authors.forename: H
authors.initials: H
authors.lastname: Joyeux
authors.forename: J
authors.initials: J
authors.lastname: Cosme
authors.forename: F P
authors.initials: FP
authors.lastname: Guengerich
authors.forename: P
authors.initials: P
authors.lastname: Maurel
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D001711:Biotransformation; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D018076:DNA, Complementary; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology*; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D010084:Oxidation-Reduction; D054328:Proton Pump Inhibitors; D013379:Substrate Specificity
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D018076:DNA, Complementary; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D003577:Cytochrome P-450 Enzyme System; D009853:Omeprazole